May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
A Report From Clinical Evaluations of a New Liquid Gel Concept Artificial Tear
Author Affiliations & Notes
  • M.T. Christensen
    Consumer Products Clinical, Alcon Laboratories Inc, Fort Worth, TX
  • D.L. Meadows
    Consumer Products Clinical, Alcon Laboratories Inc, Fort Worth, TX
  • M.R. Tudor
    Consumer Products Clinical, Alcon Laboratories Inc, Fort Worth, TX
  • R.P. Stone
    Consumer Products Clinical, Alcon Laboratories Inc, Fort Worth, TX
  • Footnotes
    Commercial Relationships  M.T. Christensen, Alcon Research LTD., E; D.L. Meadows, Alcon Research LTD., E; M.R. Tudor, Alcon Research LTD., E; R.P. Stone, Alcon Research LTD., E.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 274. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.T. Christensen, D.L. Meadows, M.R. Tudor, R.P. Stone; A Report From Clinical Evaluations of a New Liquid Gel Concept Artificial Tear . Invest. Ophthalmol. Vis. Sci. 2006;47(13):274.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate efficacy and performance characteristics of a new Concept Tear.

Methods: : The Concept Tear (Alcon Labs, Inc.) is a multi–dose formulation with buffer ingredients that work in concert to provide preservative efficacy without traditional preservatives. Like original Systane® Lubricant Eye Drops, it contains PEG–400 and propylene glycol as active demulcents with HP–Guar as a gelling agent. Unlike the original Systane, it is a structured gel in the bottle. Two clinical studies are summarized herein. Study 1: 135 dry eye patients (45 per arm) were enrolled in a randomized, double masked, parallel study of 6 wks duration. Eligible patients had to demonstrate a sum > 3 NEI corneal staining score and need artificial tears at least "some of the time". Controls contained Carboxymethylcellulose 0.5% (Unit Dose) and Carboxymethylcellulose 0.5% with PURITE (Allergan, Inc). Signs/symptoms were monitored weekly. Study 2: Acute comfort & blur comparison were made between the new Concept Tear and a Carboxymethylcellulose 1% tear with PURITE (Allergan, Inc). This was a double masked, randomized, 2–period crossover study of one dose duration. Drops were administered OU per randomization. Drop instillation comfort, overall acceptability and 3 minute blur profile comparisons were made.

Results: : Study 1: A statistically significant reduction in corneal staining change from baseline for the new Concept Tear (p=0.05) was found at 6 weeks vs Carboxymethylcellulose 0.5% with a trend in favor of the concept tear (p=0.07) vs Carboxymethylcellulose 0.5% Unit Dose. A significant reduction from baseline in symptoms was observed for all products tested. Study 2: No significant differences in drop comfort was seen, but there was a significant difference favoring the Concept Tear (p=0.0008) in drop acceptability with significantly less blurring (p < 0.0001) than the Carboxymethylcellulose 1% tear.

Conclusions: : These studies showed that the new Concept Tear demonstrated statistically significant reductions in corneal staining in a 6 wk study and was more acceptable with less blurring in an acute evaluation than a Carboxymethylcellulose 1% formulation.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×